MYMelis Gokce Kocer Yazici

Melis Gokce Kocer Yazici

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Melis Gokce Kocer Yazici has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Toward Non-Hormonal Treatment of Endometriosis: Selective Antiproliferative and Pro-Apoptotic Effects of a Boron–Curcumin–Piperine Combination on Eutopic Endometrial Cells from Women with Endometriosis

    by Mert Yesiladali, Zehra Omeroglu Ulu, Naz Unsal, Oya Alagoz, Melis G. Kocer Yazici, Rukset Attar, Fikrettin Sahin, Erkut Attar

    Background/Objectives: Current medical treatments for endometriosis are largely hormonal and are limited by side effects and recurrence. We investigated whether a combination of sodium pentaborate pentahydrate, curcumin, and piperine selectively inhibits eutopic endometrial cells from women with endometriosis. Methods: Stromal- and glandular-enriched primary cultures were established from endometrial biopsies of four women with surgically and histologically confirmed endometriosis and four women without endometriosis. Cells were treated with the combination (50–500 μg/mL) for 24–72 h. Viability was measured by MTS assay, and half-maximal inhibitory concentrations (IC50) were estimated for each donor. Apoptosis was assessed by annexin V/propidium iodide flow cytometry at each donor’s approximate IC50. Results: Viability decreased in a dose- and time-dependent manner. At 48 h, IC50 values were approximately two-fold higher in control-derived than in endometriosis-derived cells for both glandular (321.3 ± 89.6 vs. 160.4 ± 40.1 μg/mL) and stromal (351.8 ± 59.4 vs. 179.0 ± 29.9 μg/mL) cells (selectivity indices 2.00 and 1.97), with complete separation between groups (Cohen’s d 2.3 and 3.7; Mann–Whitney p = 0.029, the minimum attainable with four donors per group). The combination increased apoptosis compared with untreated cells from the same donor in both glandular (54.5 ± 17.2% vs. 8.7 ± 4.9%; p = 0.022) and stromal (55.2 ± 8.0% vs. 8.4 ± 6.5%; p < 0.001) cells, with no difference between cell types (p = 0.95). Conclusions: This non-hormonal combination selectively reduced the viability of eutopic endometrial cells from women with endometriosis and induced apoptosis in these cells in vitro, with comparable potency in the enriched stromal and glandular fractions. These preliminary findings warrant validation in lesion-derived cells and in vivo models.

  • Reassessing the Luteinizing Hormone/Follicle‐Stimulating Hormone Ratio in Polycystic Ovary Syndrome: Associations With a Possible Neuroendocrine and Anti‐Müllerian Hormone‐Related Phenotype

    by Mert Yesiladali, Melis Yazici, Zeynep Ece Utkan Korun, Rukset Attar, Erkut Attar, Fahrettin Kelestimur

    Purpose: To comprehensively reassess the clinical and metabolic significance of the luteinizing hormone (LH) to follicle‐stimulating hormone (FSH) ratio in women with polycystic ovary syndrome (PCOS), and to investigate whether it is associated with a clinical and hormonal pattern consistent with a possible neuroendocrine‐dominant subgroup, distinguishable from insulin‐related metabolic presentation. Design: Observational cross‐sectional study. Methods: This retrospective cross‐sectional study included 316 women diagnosed with PCOS according to the Rotterdam criteria at a tertiary university hospital. Patients were categorised based on their LH:FSH ratio (using a cut‐off of 2) and their PCOS phenotypes (Phenotypes A, B, C, and D). Clinical, hormonal, and metabolic parameters, including anti‐Müllerian hormone (AMH) levels and ovarian volume, were compared across groups. Results: Among 316 patients, 18.35% had an LH:FSH ratio >2. A strong positive correlation was found between LH:FSH ratio and AMH levels ( r = 0.65, p < 0.001), and a significant correlation was observed with ovarian volume ( r = 0.20, p = 0.001) and polycystic ovarian morphology (mean LH:FSH 1.59 vs. 1.15, p < 0.001). Patients with phenotype D (OA + PCOM, non‐hyperandrogenic PCOS) exhibited the highest LH:FSH ratio (1.75 ± 0.87). Higher LH:FSH ratios were associated with oligo/amenorrhea (1.59 vs. 1.22, p < 0.001), anovulation (1.66 vs. 1.16, p < 0.001), and lower midluteal progesterone (ρ = −0.28, p < 0.001), but not with serum androgens or Ferriman‐Gallwey scores. Weak positive correlations were observed with insulin levels (ρ = 0.18, p = 0.022) and HOMA‐IR (ρ = 0.18, p = 0.021), but no significant associations were found with BMI, glucose tolerance, or lipid profile. Conclusion: A high LH:FSH ratio is associated with a clinical and hormonal pattern—including elevated AMH levels, prominent PCOM, and anovulation—that may be consistent with a neuroendocrine‐dominant presentation of PCOS, rather than metabolic or androgenic disturbances. If confirmed by prospective studies, this association could inform more individualised therapeutic approaches.

  • Endometrial Siklus ve Reseptivite

    by Melis Gökçe Koçer Yazıcı, Erkut Attar

  • Does Severe Endometriosis have an Effect on Embryo Morphokinetic Parameters?

    by Feyzan Sezer, Melis Gokce Kocer Yazici, Gonul Ozer, Hakan Kadir Yelke, Gulcin Ozkara


  • Open Access

    Comparing the results of human chorionic gonadotropin and dual triggering protocols in consecutive IVF cycles of women with poor ovarian response: A retrospective case-control study.

    by Melis Gokce Kocer Yazici, Gulcin Ozkara, Mert Yesiladali, Ece Gumusoglu Caglar, Oya Algoz, Erkut Attar

    Purpose Bolus administration of GnRH analogs mimics physiological ovulation and adding GnRH-a to hCG (“dual triggering”) to induce final oocyte maturation stimulates the luteinizing hormone surge which improves IVF outcomes by decreasing immature oocyte rates. Effects of dual triggering on oocytes have been investigated in previous studies. However, retrieved oocytes in consecutive hCG and dual triggering cycles of poor responder(POR) patients has not been studied yet. In this study, we aimed to examine the retrieved/mature oocyte counts after administering hCG and dual triggering to POR patients in their consecutive IVF cycles. Method A total of 54 patients with two consecutive cycles within two years were included into this single-centered, retrospective cohort study that was conducted at Yeditepe University Hospitals, Istanbul, Turkey, between 2014 and 2021. All patients were diagnosed with POR according to the Bologna Criteria (2011). Dual vs hCG triggering protocols were compared using Wilcoxon test in terms of oocyte count and maturation. Results Although a statistically significant difference was observed between the ages of patients in their consecutive IVF cycles, it did not have a clinical significance (38.80±3.72 vs 38.17±3.75, p0.05). No statistically significant difference was found in terms of total and mature oocytes between two protocols. Conclusion The results demonstrated that the choice of triggering method, whether hCG or dual triggering, did not significantly influence neither the retrieved oocyte count nor maturation in POR patients.

  • Open Access

    Differentiating Polycystic Ovary Syndrome from Adrenal Disorders

    by Mert Yesiladali, Melis G. K. Yazici, Erkut Attar, Fahrettin Kelestimur

    Although polycystic ovary syndrome (PCOS) is primarily considered a hyperandrogenic disorder in women characterized by hirsutism, menstrual irregularity, and polycystic ovarian morphology, an endocrinological investigation should be performed to rule out other hyperandrogenic disorders (e.g., virilizing tumors, non-classical congenital adrenal hyperplasia (NCAH), hyperprolactinemia, and Cushing’s syndrome) to make a certain diagnosis. PCOS and androgen excess disorders share clinical features such as findings due to hyperandrogenism, findings of metabolic syndrome, and menstrual abnormalities. The diagnosis of a woman with these symptoms is generally determined based on the patient’s history and rigorous clinical examination. Therefore, distinguishing PCOS from adrenal-originated androgen excess is an indispensable step in diagnosis. In addition to an appropriate medical history and physical examination, the measurement of relevant basal hormone levels and dynamic tests are required. A dexamethasone suppression test is used routinely to make a differential diagnosis between Cushing’s syndrome and PCOS. The most important parameter for differentiating PCOS from NCAH is the measurement of basal and ACTH-stimulated 17-OH progesterone (17-OHP) when required in the early follicular period. It should be kept in mind that rapidly progressive hyperandrogenic manifestations such as hirsutism may be due to an androgen-secreting adrenocortical carcinoma. This review discusses the pathophysiology of androgen excess of both adrenal and ovarian origins; outlines the conditions which lead to androgen excess; and aims to facilitate the differential diagnosis of PCOS from certain adrenal disorders.